Fundraising Success Enables Clinical Trials for Cade Jobsis' Rare Genetic Disease

The Jobsis family has successfully raised $1.15 million to enroll their 4-year-old son, Cade Jobsis, in clinical trials aimed at treating his rare genetic disease, SPG50. This fundraising effort follows an initial $3 million raised alongside three other families to cover the cost of the drug itself. The additional funds are necessary to facilitate hospital treatment, allowing the trials to proceed as planned by the end of this year.

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic diseaseA baby’s life is saved with personalized gene therapyGoodNewsNetwork

Cade's condition stems from inheriting defective copies of a gene from both parents, which impairs his body’s ability to produce a crucial protein. Emma Jobsis, Cade's mother, explained that the gene therapy aims to provide a functional copy of the gene, essentially restoring the "instruction manual" that Cade's body lacks. The therapy, named Melpida, was developed by Terry Pirovolakis, whose son was diagnosed with the same condition at 15 months old. The name Melpida combines Pirovolakis's son's name, Michael, with the Greek word for hope, Elpida.

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic diseaseA baby’s life is saved with personalized gene therapyGoodNewsNetwork

Emma Jobsis highlighted a significant gap in research for rare diseases, stating, “There just isn't research. There aren't any clinical trials there.” This sentiment reflects a broader concern among families affected by rare diseases, emphasizing the need for accessible clinical trials beyond isolated compassionate use cases. The Jobsis family’s initiative aims to pave the way for more families to access similar treatments.

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic disease

The first child in the trial cohort is scheduled to begin treatment in Texas in early December 2023. The Jobsis family anticipates that the next participant will be identified by the end of 2025, marking a significant step forward in the quest for effective treatments for rare genetic disorders.

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic disease

While the fundraising success is a positive development, some critics argue that the reliance on private fundraising for medical research highlights systemic issues in funding for rare diseases. The Jobsis family's experience underscores the challenges faced by families navigating the healthcare system for rare conditions, where funding and research opportunities are often limited.

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic disease

• “Cade, he received a bad copy from me and a bad copy from my husband of the exact same gene,” — Emma Jobsis, Cade's Mother

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic disease

• “There's a huge gap in medicine and research for rare and ultra-rare diseases.” — Emma Jobsis

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic disease

• “The biggest blessing for us is that Cade doesn't know anything's wrong.” — Emma Jobsis

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic disease

The successful fundraising campaign for Cade Jobsis represents a critical milestone in the fight against rare genetic diseases. As clinical trials commence, the Jobsis family hopes to not only improve Cade's health but also inspire broader changes in the accessibility of treatments for rare conditions. The ongoing efforts highlight the intersection of personal determination and the need for systemic change in medical research funding.

Cure for Cade raises enough to continue with clinical trials for child’s rare genetic disease